Brightsurf Science News & Current Events

October 08, 2016
Ribociclib improves progression-free survival in advanced breast cancer
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.

True burden of head and neck cancer in France underestimated by more than one-third
A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to two presentations at the ESMO 2016 Congress in Copenhagen.

Targeting estrogen receptor improves progression-free survival in advanced breast cancer
Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen.

Niraparib significantly improves outcome of ovarian cancer patients in landmark trial
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine (NEJM).

Chinese scientists unravel weapons of defense against 'cotton cancer'
A group of Chinese scientists led by Professor Guo Huishan from Institute of Microbiology of Chinese Academy of Sciences discovered that trans-kingdom small RNAs can be used to protect crops from infection of fungal pathogens.

Obesity-linked conditions are projected to rise sharply in children
Researchers' global estimates indicate that by 2025, some 268 million children aged 5 to 17 years may be overweight, including 91 million obese, assuming no policy interventions have proven effective at changing current trends.

Satellites see Hurricane Matthew's center near coastal South Carolina
Hurricane Matthew's center was near the coast of South Carolina during the morning of Oct.

Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumors were reported today at the ESMO 2016 Congress in Copenhagen.

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 Congress in Copenhagen.

Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer
Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.